SG Americas Securities LLC Has $741,000 Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE
by Tristan Rich · The Markets DailySG Americas Securities LLC decreased its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 74.3% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 32,204 shares of the biopharmaceutical company’s stock after selling 93,225 shares during the quarter. SG Americas Securities LLC’s holdings in Ultragenyx Pharmaceutical were worth $741,000 as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Ultragenyx Pharmaceutical by 14.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock valued at $8,414,000 after acquiring an additional 29,984 shares in the last quarter. Creative Planning purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth approximately $454,000. American Century Companies Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $366,000. M&T Bank Corp boosted its holdings in shares of Ultragenyx Pharmaceutical by 19.7% during the second quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock worth $263,000 after purchasing an additional 1,192 shares during the period. Finally, Amundi grew its position in Ultragenyx Pharmaceutical by 1,560.4% during the second quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock valued at $3,913,000 after purchasing an additional 93,189 shares in the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 8,135 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $185,478.00. Following the transaction, the executive vice president directly owned 76,346 shares of the company’s stock, valued at $1,740,688.80. This represents a 9.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Howard Horn sold 8,409 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.70, for a total value of $190,884.30. Following the completion of the sale, the chief financial officer directly owned 86,669 shares of the company’s stock, valued at $1,967,386.30. This represents a 8.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 109,556 shares of company stock valued at $2,490,138. Corporate insiders own 5.20% of the company’s stock.
Ultragenyx Pharmaceutical Stock Down 2.6%
NASDAQ RARE opened at $23.30 on Friday. The stock has a market capitalization of $2.29 billion, a PE ratio of -3.99 and a beta of 0.25. Ultragenyx Pharmaceutical Inc. has a 12-month low of $18.29 and a 12-month high of $42.37. The company has a 50 day moving average price of $22.09 and a two-hundred day moving average price of $27.57.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The business had revenue of $207.28 million for the quarter, compared to analyst estimates of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The business’s revenue for the quarter was up 25.5% compared to the same quarter last year. During the same quarter last year, the company earned ($1.39) EPS. As a group, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. Wedbush reiterated a “neutral” rating and issued a $25.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, February 17th. The Goldman Sachs Group cut shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and lowered their price target for the company from $61.00 to $25.00 in a report on Tuesday, March 24th. HC Wainwright cut their price objective on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Guggenheim reduced their price objective on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research report on Monday, January 5th. Finally, Wells Fargo & Company lowered their target price on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 30th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $60.47.
Read Our Latest Stock Report on Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Profile
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.
The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.
Featured Stories
Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report).